Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of ADC189 Tablet vs Granule and Safety of Ultra-high Dose in Healthy Men
NCT06428903Phase 1Completed
- Sponsor
- Jiaxing AnDiCon Biotech
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deunoxavir marboxil in influenza (3 arms), sponsored by Jiaxing AnDiCon Biotech. Primary endpoints: Pharmacokinetic performance of ADC189 Granules at 15 days, Pharmacokinetic performance of ADC189 Tablet at 15 days and 2 more. Started Mar 2024; status: completed.
02
Drugs
deunoxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06428903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428903.